Get Help Now >

Bibliography

Previous Page

 
  1. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology. 2000;2:13-30.
  2. Barat I, et al. The consumption of drugs by 75-year-old individuals living in their own homes. European Journal of Clinical Pharmacology. 2000;56:501-509.
  3. Seget S. Theta Reports. Pain Management: World Prescription Drug Markets. Report No. 1217, March 2003. PJB Medical Publications Inc. New York, NY. 
  4. Gabriel SE, et al. The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis and Rheum. 1993;36:447-59.
  5. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-2. British Medical Journal (Clin Res Ed). 1986;292:1190-1.
  6. National Totals for Prescription of Antiarthritic Drug Therapies in Canada. Montreal: IMS Canada; 1997.
  7. Brooks P, et al. Nonsteroidal anti-inflammatory drugs – differences and similarities. The New England Journal of Medicine. 1991;324:1716-1725.
  8. Green GA. Understanding NSAIDS: from aspirin to COX-2. Clin Cornerstone. 2001;3:50-59.
  9. Tannenbaum H, et al. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: the Second Canadian Consensus Conference. Canadian Journal of Clinical Pharmacology. 2000; 7(Suppl A):4A-16A.
  10. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905-1915.
  11. National Institute of Health and Clinical Excellence (NICE). Guidelines on the use of Cox II selective inhibitors. Technology Appraisal No. 27. London, NICE; 2001.
  12. Graham D. NSAID ulcers: prevalence and prevention. Modern Rheumatology. 2000;10:2-7.
  13. Brooks P, et al. Nonsteroidal anti-inflammatory drugs – differences and similarities. New England Journal of Medicine. 1991;324:1716-1725.
  14. Zhang W, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage. 2008;16:137-162.
  15. Garcia F. Catabolic events in osteoarthrtitis cartilage. Osteoarthritis and Cartilage. 1999;7:308-309.
  16. Blanco FJ, et al. Chondrocytes in OA die by apoptosis: a possible explanation for the etiopathogenesis of OA. Arthritis and Rheumatism. 1998;38:540-545.
  17. Geng Y, et al. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. Journal of Immunology. 1995;155:796-801.
  18. Carey-Beth J, et al. A review of articular cartilage pathology and the use of glucosamine sulfate. Journal of Athletic Training. 2001;36:413-419.
  19. Ishiguro N, et al. Mechanism of cartilage destruction in osteoarthritis. Nagoya Journal of Medical Science. 2002;65:73-84.
  20. Poole AR, et al. Composition and structure of articular cartilage: a template for tissue repair. Clinical Orthopedics. 2001;391:S26-33.
  21. Vidal BC, et al. Articular cartilage: collagen II—proteoglycans interactions. Availability of reactive groups. Variation in birefringence and differences as compared to collagen I. Acta Histochem. 1988;83:189-205.
  22. Aigner T, et al. Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis-structure, chaos and senescence. Nat Clin Pract Rhematol. 2007;3:391-399.
  23. Felson DT, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Annals of Internal Medicine. 2000;133:635-646.
  24. Reife RA, et al. Pathological cartilage degradation in human arthritides. In: Woessner J, et al. Joint Cartilage Degradation, Basic and Clinical Aspects. New York: Informa Health Care; 1995.
  25. Bollet AJ, et al. Biochemical findings in normal and osteoarthritic articular cartilage, II: chondroitin sulfate concentration and chain length, water, and ash content. Journal of Clinical Investigation. 1966;45:1170-1177.
  26. Kempson GE. Relationship between tensile properties of articular cartilage from the human knee and age. Annals of Rheumatic Diseases. 1982;41:508-511.
  27. Theis KA, et al. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. Journal of Women’s Health. 2007;16:441-453.
  28. Hootman JM, et al. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity-limitation-United States, 2003-2005. MMWR. 2006;55:1089-1092.
  29. Hootman JM, et al. Projections of U.S. prevalence of arthritis and associated activity limitations. Arthritis and Rheumatism. 2006;54:226-229.
  30. Garbiel SE, et al. Direct medical costs unique to people with arthritis. Journal of Rheumatology. 1997; 24:719-725.
  31. Maetzel A, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparison study. Annals of Rheumatic Diseases. 2004;63:395-401.
  32. Gupta S, et al. The economic burden of disabling hip and knee osteoarthritis from the perspective of individuals living with the condition. Rheumatology. 2005;44:1531-1537.
  33. Merrill C. Hospital Stays Involving Musculoskeletal Procedures, 1997-2005. Health Care Cost and Utilization Project. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb34.jsp. Accessed on October 2, 2009.
  34. Baum C, et al. Utilization of nonsteroidal anti-inflammatory drugs. Arthritis and Rheumatism. 1985;28:686-692.
  35. Linsell L, et al. Prospective study of elderly people comparing treatments following first primary care consultation for a symptomatic hip or knee. Family Practice. 2005;22:118-125.
  36. Hochberg MC, et al. Preferences in the management of osteoarthritis of the hip and knee: results of a survey of community-based rheumatologists in the United States. Arthritis Care and Research. 1996;9:170-176.
  37. DeHann MN, et al. Knee osteoarthritis clinical practice guidelines-how are we doing? Journal of Rheumatology. 2007;34:2099-2105.
  38. Wilcox CM, et al. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal anti-inflammatory drugs. Journal of Rheumatology. 2005;32:2218-2224.
  39. Wilcox CM, et al. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal anti-inflammatory drugs. Journal of Rheumatology. 2005;32:2218-2224.
  40. Singh G. Gastrointestinal complications of prescription and over-the-counter anti-inflammatory drugs: a view from the ARAMIS data bank. Arthritis, Rheumatism, and Aging Medical Information System. American Journal Ther. 2000;7:115-121.
  41. Kaufman DW, at al. Recent patterns of medication use in the ambulatory adult population in the United States. The Slone Survey. JAMA. 2002;287:337-44.
  42. Curhan GC, et al. Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf. 2002;11:687-693.
  43. Biossonnault WG, et al. Risk factors for anti-inflammatory-drugs- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports Phys Ther. 2002;32:510-517.
  44. Hauser R, et al. An observational study of patients with unresolved neck pain who were treated with dextrose prolotherapy at an outpatient charity clinic in rural Illinois. Practical Pain Management. 2007;7(8):56-69.
  45. Hauser R, et al. A retrospective study on dextrose prolotherapy for unresolved knee pain at an outpatient charity clinic in rural Illinois. Journal of Prolotherapy. 2009;1:11-21.
  46. Hauser R. et al. A retrospective study on Hackett-Hemwall dextrose prolotherapy for chronic hip pain at an outpatient charity clinic in rural Illinois. Journal of Prolotherapy. 2009;2:76-88.
  47. Hauser, R, et al. Dextrose prolotherapy and pain of chronic TMJ dysfunction. Practical Pain Management. 2007;7(9):49-57.
  48. Barat I, et al. The consumption of drugs by 75-year-old individuals living in their own homes. European Journal of Clinical Pharmacology. 2000;56:501-509.
  49. Chiroli S, et al. Utilization pattern of nonspecific nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in a local health service unit in northeast Italy. Clin Drug Invest. 2003;23:751-760.
  50. Palmoski MJ, et al. Effect of salicylate on proteoglycan metabolism in normal canine articular cartilage in vitro. Arthritis and Rheumatism. 1979;22:746-754.
  51. Palmoski MJ, et al. Aspirin aggravates the degeneration of canine joint cartilage caused by immobilization. Arthritis and Rheumatism. 1982;25:1333-1342.
  52. Palmoski MJ, et al. Effect of salicylate and indomethacin on glycosaminoglycan and prostaglandin E2 synthesis in intact canine cartilage ex vivo. Arthritis Rheum. 1984;27:398-403.
  53. Slowman-Kovacs SD, et al. Effects of salicylates on chondrocytes from osteoarthritic and contralateral knees of dogs with unilateral anterior cruciate ligament transaction. Arthritis and Rheumatism. 1989;32:486-489.
  54. Palmoski MJ, et al. Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritis cartilage. Arthritis and Rheumatism. 1980;23:83-91.
  55. Palmoski MJ, et al. Effects of some nonsteroidal anti-inflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arthritis and Rheumatism. 1980;23:1010-1020.
  56. Brandt KD, et al. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Clinical Orthopedics. 1986;213:84-91.
  57. Palmoski MJ, et al. Relationship between matrix proteoglycan content and the effects of salicylate and indomethacin on articular cartilage. Arthritis and Rheumatism. 1983;26:528-531.
  58. Mckenzie LS, et al. Osteoarthrosis: uncertain rationale for anti-inflammatory drug therapy. Lancet.1:908-912.
  59. Dekel S, et al. The effect of anti-inflammatory drugs on glycosaminoglycan sulphation in pig cartilage. Prostaglandins Med. 1980;4:133-140.
  60. Mitrovic D, et al. Anti-inflammatory drugs, prostanoid and proteoglycan production by cultured bovine articular chondrocytes. Prostaglandins. 1984;28:417-434.
  61. Serni U, et al. Is there preliminary in-vivo evidence for an influence of nonsteroidal anti-inflammatory drugs on progression in osteoarthritis? Part II-evidence from animal models. Osteoarthritis and Cartilage. 1999;7:351-352.
  62. Kalbhen DA. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex. Z Rheumatol. 1982;41:202-211.
  63. Chang JK, et al. Effects of non-steroidal anti-inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats. Toxicology. 2006;228:111-123.
  64. Matsuda K, et al. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatology International. 2006;26:991-995.
  65. Schwartz Z, et al. The effect of prostaglandin E2 on costochondral chondrocyte differentiation is mediated by cyclic adenosine 3’, 5’-monophosphate and protein kinase C. Endocrinology. 1998;139:1825-1834.
  66. O’Keefe RJ, et al. Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J Bone Miner Res. 1992;7:397-404.
  67. Miyamoto M, et al. Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. Osteoarthritis and Cartilage. 2003;11:644-652.
  68. Clark CA, et al. Differential regulation of EP receptor during chondrogenesis and chondrocyte maturation. Biochem Biophys Res Commun. 2005;328:764-776.
  69. Brochhausen C, et al. Cyclooxygenases and prostaglandin E2 in growth plate chondrocytes in vitro and in situ – Prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res Ther. 2006;8:1-21.
  70. Brandt K. The mechanism of action of nonsteroidal anti-inflammatory drugs. Journal of Rheumatology. 1991;13:120-121.
  71. Green GA. Understanding NSAIDs: from aspirin to Cox-2. Clin Cornerstone. 2001;3:50-59.
  72. Maroudas A, et al. Cartilage of the hip joint. Topographical variation of glycosaminoglycan content in normal and fibrillated tissue. Annals of Rheumatologic Diseases. 1973;32:1-8.
  73. Mankin HJ, et al. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. Journal of Bone and Joint Surgery. 1970;52A:424-431.
  74. McKenzie LS, et al. Effect of anti-inflammatory drugs on sulphated glycosaminoglycan synthesis in aged human articular cartilage. Annals of Rheumatologic Diseases. 1976;35:487-497.
  75. Dingle JT. Prostaglandins in human cartilage metabolism. Journal of Lipid Mediators. 1993;6:303-312.
  76. Dingle JT. The effect of nonsteroidal anti-inflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis and Cartilage. 1999;7:313-314.
  77. Dingle JT. The effects of NSAIDs in human articular cartilage GAG synthesis. European Journal of Rheumatology. 1996;16:47-52.
  78. Manicourt DH, et al. Effect of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage. British Journal of Pharmacology. 1994;113:1113-1120.
  79. Rainsford KD, et al. Effect of meloxicam, compared with other NSAIDs on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ cultures. Pharm Pharmacol. 1997;49:991-998.
  80. Atkins D, et al. Role of prostaglandins in bone metabolism: a review. Journal of the Royal Society of Medicine. 1979;72:27-34.
  81. Wallace JL, Tigley AW. Review article: new insights into prostaglandins and mucosal defense. Aliment Pharmacol Ther. 1995;9:227-235.
  82. Notoya K, et al. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. Journal of Immunology. 2000;165:3402-3410.
  83. Jeffrey JE, et al. Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro. Arthritis Research & Therapy. 2007;9:R129-R130.
  84. DiBattista JA, et al. Prostaglandin E2 stimulates insulin-like growth factor binding protein-4 expression and synthesis in cultured human articular chondrocytes: possible mediation by Ca++calmodulin regulated processes. Journal of Cell Biochemistry. 1997;65:408-419.
  85. O’Keefe RJ, et al. Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J Bone Miner Res. 1992;7:397-404.
  86. Lowe GN, et al. Effects on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of secondary messengers. Endocrinology. 1996;137:2208-2216.
  87. DiBattista JA, et al. Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of an effector autocrine loop involving insulin-like growth factor I. Mol Cell Endocrinol. 1996;123:27-35.
  88. DiBattista JA, et al. Prostaglandin E2 up-regulates insulin-like growth factor binding-3-expression and synthesis in human articular chondrocytes by a cAMP-independent pathway: Role of calcium and protein kinase A and C. Journal of Cell Biochemistry. 1996;62:1-14.
  89. Geng Y, et al. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. Journal of Immunology. 1995;155:796-801.
  90. Vane JR, et al. Inducible isoforms of cycooxygenase and nitric-oxide synthase in inflammation. Proceedings of the National Academy of Science USA. 1994;91:2046-2050.
  91. Ristimaki A, et al. Induction of cyclooxygenase-2 by interleukin-1. Journal of Biol Chem. 1994;269:11769-11775.
  92. Blanco F, et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. The Journal of Rheumatology. 1999;26:1366-1373.
  93. Baasleer CT, et al. Effects of tiaprofenic acid and acetylsalicylic acid on human articular chondrocytes in 3-dimensional culture. Journal of Rheumatology. 1992;19:1433-1438.
  94. Mastbergen SC, et al. Differential direct effects of cyclooxygenase–1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Research & Therapy. 2006;8:R2-13.
  95. Goldring MB, et al. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res. 2004;427:Suppl:S37-46.
  96. Dubois RN, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
  97. Martel-Pelletier J, et al. Cyclooxygenase-2 and prostaglandin in articular tissues. Seminars in Arthritis and Rheumatism. 2003;33:155-167.
  98. Amin AR, et al. Superinduction of cyclooxygenase-2 in activity in human osteoarthritis-affected cartilage: Influence of nitric oxide. Journal of Clinical Invest. 1997;99:1231-1237.
  99. Pelletier JP, et al. Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. Journal of Rheumatology. 1998;25:2417-2424.
  100. Geng Y, et al. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. Journal of Immunology. 1995;155:796-801.
  101. Aoyama T, et al. PGE2 signal through EP2 promotes the growth of articular chondrocytes. J Bone Miner Res. 2005;20:377-389.
  102. Alvarez-Soria MA, et al. Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis and Cartilage. 2008; Dec;16(12):1484-93.
  103. Coke H. Long term indomethacin therapy of coxarthrosis. Ann Rheum Dis. 1967;26:346-350.
  104. Milner JC. Osteoarthritis of the hip and indomethacin. J Bone Joint Surg (Br). 1972;54B:752-756.
  105. Ronningen H, et al. Indomethacin hips. Acta Orthop Scan. 1977;48:556-561.
  106. Serup J, et al. Salicylate arthropathy: accelerated coxarthrosis during long-term treatment with acetyl salicylic acid. Praxis. 1981;70:359-362.
  107. McKenzie LS, et al. Osteoarthrosis: uncertain rationale for anti-inflammatory drug therapy. Lancet. 1976;i:908-909.
  108. Newman NM, et al. Acetabular bone destruction related to non-steroidal anti-inflammatory drugs. The Lancet. 1985; July 6:11-13.
  109. Ronningen H, et al. Indomethacin treatment in osteoarthritis of the hip joint. Acta Orthop Scand. 1979;50:169-174.
  110. Solomon L. Drug-induced arthropathy and necrosis of the femoral head. J Bone and Joint Surgery. 1973;55B: 246-261.
  111. Huskisson HC, et al. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. Journal of Rheumatology. 1995;22:1941-1946.
  112. Ledingham J, et al. Radiographic progression of hospital referred osteoarthritis of the hip. Annals of Rheumatic Diseases. 1993;52:263-267.
  113. Ronningen H, et al. Indometacin treatment in osteoarthritis of the hip joint. Acta Orthop Scand. 1979;50:169-174.
  114. Newman NM, et al. Acetabular bone destruction related to non-steroidal anti-inflammatory drugs. Lancet. 1958;2:11-14.
  115. Coke H. Long term indometacin therapy of coxarthrosis. Annals of Rheumatic Diseases. 1967;26:346-347.
  116. Arora JS, et al. Indocid arthropathy of hips. Proc R Soc Med. 1968;61:669-672.
  117. Rashad S, et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989;2:519-522.
  118. Dougados M, et al. Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status. Annals of Rheumatic Diseases. 1996;55:356-362.
  119. Reijman M, et al. Is there an association between the use of different types of nonsteroidal anti-inflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 2005;52:3137-3142.
  120. Buckland-Wright JC, et al. Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo-controlled trial of NSAID therapy. Journal of Rheumatology. 1995;22:937-943.
  121. Lane NE, et al. All About Osteoarthritis. Oxford University Press, Oxford England; 2002: 19.
  122. Andriacchi TP, et al. Methods for evaluating the progression of osteoarthritis. Journal of Rehabilitation Research & Development. 2000;37:163-170.
  123. Schnitzer T, et al. Effect of NSAIDs on knee loading in patients with osteoarthritis. Arthritis Rheum. 1990;33:S92-S97.
  124. Schnitzer T, et al. Effect of piroxicam on gait in patients with osteoarthritis of the knee. Arthritis Rheum. 1993;36:1207-1213.
  125. Blin O, et al. Quantitative analysis of walking in patients with knee osteoarthritis: a method of assessing the effectiveness of non-steroidal anti-inflammatory treatment. Ann Rheum Dis. 1990;49:990-993.
  126. Sharma L, et al. Knee adduction moment, serum hyaluronic acid level, and disease severity in medial tibiofemoral osteoarthritis. Arthritis Rheum. 1998;41:1233-1240.
  127. Gossec L, et al. Predictive factors of total hip replacement due to primary osteoarthritis: a prospective 2 year study of 505 patients. Annals of Rheumatic Diseases. 2005;64:1028-1032.
  128. Rashad S, et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989;2:519-522.
  129. Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. European Journal of Rheumatology and Inflammation. 1993;13:7-16.
  130. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002;26:139-142.
  131. Courtney P, et al. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Anna Rheum Dis. 2002;61:767-773.
  132. Zhang W, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage. 2008;16:137-162.
  133. Group for the Respect of Ethics and Excellence in Science (GREES). Recommendations for the registration of drugs used in the treatment of osteoarthritis. Annals of the Rheumatic Diseases. 1996;55:552-557.
  134. Hendrick B. FDA Issues New Warnings for Painkillers. WEB MD, Available at: http://www.webmd.com/pain-management/news/20090428/fda-issues-new-warnings-painkillers. Accessed May 13, 2009.
  135. Helidonis E, et al. The contribution of Hippocratic oak in third millennium medical practice. American Journal of Otolaryngology. 2001;22:303-305. 


 

Previous Page

 
Recomended Reading

Journal of Prolotherapy